At a series of scientific seminars with the participation of more than 1,000 domestic and international respiratory medical staff, organized by the Vietnam Respiratory Association, Vietnam Lung Association and GSK Vietnam Pharmaceutical Company Limited (GSK Viet Nam) recently coordinated the organization, Professor. Dr. Dr. Ngo Quy Chau, President of the Vietnam Respiratory Association, said: “Each COPD patient has a different medical condition, so treatment needs to be individualized to achieve optimal effectiveness. If appropriate treatment is given early and the doctor’s instructions are followed, the patient’s symptoms will be stabilized and lung function will be preserved. From there, patients can live relatively normal activities and improve their quality of life.”
To support medical staff in effective treatment, help patients improve lung function, reduce acute hospitalizations, reduce events and the risk of all-cause mortality, GSK launches triple therapy. medicine in one inhaler (once-daily, single-inhaler triple therapy) for the first time in Vietnam.
This breakthrough therapy is available in 63 countries, with pivotal scientific research, and is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Professor Paul Jones, a global expert in respiratory research, was a member of the Scientific Committee of the European Respiratory Society, and Medical Director of GSK Global Respiratory Industry, updated: “I believes that with medical evidence, GSK’s triple therapy is one of the important advances in the treatment of COPD patients at risk of exacerbation and whose symptoms are not controlled.
Evidence-based medicine shows that the FF/UMEC/VI triple therapy reduces the exacerbation rate by 44% compared to the ICS/LABA dual therapy after 12 months, the first triple therapy to reduce the exacerbation rate by 34%. Acute hospitalization and reduced all-cause mortality by 28% compared to dual bronchodilators.
Associate Professor. Dr. Dr. Nguyen Viet Nhung, Chairman of the Vietnam Lung Association, said: “We are happy that Vietnam has another breakthrough solution, contributing to helping patients have early access to the world’s scientific achievements.
In addition, we will coordinate to strengthen continuing medical education activities, clinical practice exchange as well as disease education for patients to help them recognize the risk of an acute attack early and continue treatment. appropriate triple therapy approach”.